Allergy Therapeutics PLC (AGY) 2023年年度报告「LSE」.pdf

1、Transforming livesAnnual Report and Accounts 2023Strategic report03 At a glance04 How it works06 Chairman and Chief Executive Officer review08 Market need10 Business model11 Purpose and cultural values12 Environment,social and governance 29 Strategic framework30 Key performance indicators(“KPIs”)32

2、Our products33 R&D report36 Effective risk management37 Principal risks and uncertainties40 Financial reviewGovernance42 Board of Directors44 Corporate governance report48 How the Board engages with stakeholders49 Nomination Committee report50 Audit and Risk Committee report52 Directors remuneration

3、 report60 Directors report62 Statement of Directors responsibilitiesFinancial statements63 Independent auditors report 71 Consolidated income statement72 Consolidated statement of comprehensive income73 Consolidated statement of financial position74 Consolidated statement of changes in equity75 Cons

4、olidated cash flow statement76 Notes to the consolidated financial statements118 Company balance sheet119 Company statement of changes in equity 120 Notes to the Company financial statements124 Glossary125 Shareholder informationContents01Allergy Therapeutics plc Annual Report and Accounts 2023throu

5、gh our vision of breaking new ground in immunology treatment through specialist expertise.Delivered through our strategyExpanding in EuropeStrong pipelineUS entrySee more on page 29Underpinned by our cultureVisionaryPatient FirstMenschlichkeitCommitmentSee more on page 11Our purpose is to transform

6、patients lives02Allergy Therapeutics plc Annual Report and Accounts 2023Allergen immunotherapy addresses the cause of allergy,not just the symptoms.LocationsSales Sales by country%Sales by product%Germany|53%Spain|16%Austria|8%Netherlands|7%Italy|5%Switzerland|5%UK|3%Czech&Slovak|2%Other|1%Pollinex